Market data not provided in the source material.
No Federal Reserve or Treasury rate information included in this report.
The macro environment remains challenging with Middle East-linked disruptions weighing on various sectors, though underlying demand patterns show resilience in key industries like semiconductors. Corporate earnings are delivering mixed but generally positive surprises, suggesting companies are navigating the current headwinds better than feared. The wave of M&A activity (particularly in healthcare with the BIIB/APLS and LLY/CNTA deals) indicates strategic buyers see value in current market conditions.
Trump's social media post essentially confirms the WSJ report about the US exiting Middle East conflicts, telling other countries to buy American energy or "take it" from Hormuz, declaring "Iran has been, essentially, decimated" and that other nations will need to "start learning how to fight for yourself" (social media post). The Middle East disruption is already impacting supply chains, with companies like VAT Group citing regional issues for revenue shortfalls.
BIIB announced it will acquire APLS for $41 per share in cash (~$5.6B) plus a CVR worth up to $2 per share, representing a massive premium to APLS's Monday close of $17.09. The transaction is expected to be increasingly accretive to Biogen's Non-GAAP EPS starting in 2027.
LLY will buy CNTA for $38 per share in cash (~$6.3B) plus a CVR worth up to $9 per share for total potential value of $47, well above CNTA's Monday close of $27.58. Centessa is developing treatments for excessive daytime sleepiness and other neurological conditions.
MKC delivered upside with Q1 adjusted EPS of 66¢ versus Street expectations of 59¢, driven by revenue of $1.87B (vs. $1.79B expected). Organic growth of 1.2% fell slightly short of the 1.4% expectation, but gross margins expanded 100 basis points. The lack of guidance raise despite the beat might disappoint, though multiple reports suggest a Unilever deal could be announced imminently.
NKE insists it doesn't plan to sell Converse, but Authentic Brands has expressed interest in buying the struggling business (Bloomberg). Investors would welcome a Converse divestiture given the brand's massive decline, with consensus modeling -25% revenue in F26 to $1.26B following -19% in F25.
CEG is targeting base EPS CAGR of 20%+ from 2026-2029 and increased its buyback authorization to $5B. For 2026, the company sees EPS of $11-12 (mid-point $11.50), slightly below consensus of $11.72.
FDS reported modest Q2 EPS upside of $4.46 versus Street $4.37, with 6.8% organic revenue growth beating the 6% expectation. The company raised full-year EPS guidance to $17.25-17.75 from prior $16.90-17.60, though operating margins fell short at 35% versus expected 35.5%.
SNX delivered strong Q1 EPS of $4.73 versus Street $3.29, driven by robust sales of $17.16B (vs. $15.55B expected) and margin expansion. Q2 guidance mid-points are well ahead with EPS of $4 versus Street $3.45.
Whoop raised $575M at a $10.1B valuation, up dramatically from its 2021 valuation of $3.6B, as the fitness wearable company prepares for an IPO (Bloomberg).
No upcoming economic data dates provided in this report.
No specific earnings calendar provided.
No specific earnings calendar provided.